Neulasta® (pegfilgrastim) | G-CSF Injection Learn about Neulasta® (pegfilgrastim).
Estimated Price $0


Domain age of is 16 years. Estimated potential revenue of this site may be up to $0 per month. We did not find any sites that have the same ID at Analytics and/or Adsence. According to our information, it is safe to visit

Monthly Visitors

Now loading ...
Apr'18 (est) 9K
Mar'18 (est) 15K
Feb'18 (est) 14K
Jan'18 (est) 10K
Dec'17 (est) 14K
Nov'17 (est) 9K
Oct'17 (est) 10K
Sep'17 (est) 11K
Aug'17 (est) 9K
Jul'17 0
Jun'17 (est) 11K
May'17 0
Apr'17 (est) 10K
Mar'17 (est) 11K
Feb'17 (est) 15K
Jan'17 (est) 19K

SiteGur Score

Now loading ...
Apr'18 -8022
Mar'18 6626
Feb'18 2582
Jan'18 -4036
Dec'17 3078
Nov'17 -2409
Oct'17 -1036
Sep'17 1669
Aug'17 -257
Jul'17 0
Jun'17 1497
May'17 0
Apr'17 -1216
Mar'17 -1482
Feb'17 -1285
Jan'17 -3899

Similar Sites

  • ED and BPH Treatment | CIALIS (tadalafil) tablets Only CIALIS for daily use (5 mg) is approved to treat erectile dysfunction and the frustrating urinary symptoms of benign prostatic hyperplasia.
  • Type 2 Diabetes Medication | JANUVIA ® (sitagliptin) tablets Get information on JANUVIA® (sitagliptin) tablets and information to help manage type 2 diabetes from the official Web site for JANUVIA.
  • Spiriva
  • VIVITROL ® | Official Site VIVITROL® (naltrexone for extended-release injectable suspension) with counseling may help with opioid or alcohol dependence. See risks & benefits.
  • TRUVADA® (emtricitabine and tenofovir disoproxil fumarate) The official web site for TRUVADA® (emtricitabine and tenofovir disoproxil fumarate).
  • Qsymia ® (Phentermine and Topiramate extended-release) Capsules CIV | Official Site - prescription weight-loss medicine Learn about Qsymia, an FDA-approved weight-loss prescription medicine that may help some patients lose weight and keep it off
  • Osteoporosis Treatment Medication FORTEO [teriparatide (rDNA origin) injection] FORTEO is an osteoporosis treatment medication. If you are an osteoporosis patient at high risk for fracture, learn how FORTEO can help treat your osteoporosis.
  • REVLIMID® (lenalidomide) Treatment for Multiple Myeloma | Mantle Cell Lymphoma | Deletion 5q Myelodysplastic Syndromes About REVLIMID® (lenalidomide) treatment for deletion 5q myelodysplastic syndromes, mantle cell lymphoma and multiple myeloma including full indications, dosing, administration, efficacy, safety & prescribing information. Important Safety Information WARNING: Risk to unborn babies, low blood counts, and blood clots Before you begin taking REVLIMID, you must read and agree to all of the instructions in the REVLIMID REMS® program (formerly known as the RevAssist® program). REVLIMID may cause serious side effects including: Possible birth defects (deformed babies) or death of an unborn baby. Females who are pregnant or who plan to become pregnant must not take REVLIMID. REVLIMID is similar to the medicine thalidomide (THALOMID®). We know thalidomide can cause severe life-threatening birth defects. REVLIMID has not been tested in pregnant females. REVLIMID has harmed unborn animals in animal testing. In females of childbearing potential, obtain 2 negative pregnancy tests before starting REVLIMID treatment. Female
  • Type 2 diabetes medication & treatment | Jardiance ® (empagliflozin) tablets Learn about a treatment option for type 2 diabetes. JARDIANCE is a prescription medicine used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. JARDIANCE is not for people with type 1 diabetes or for people with diabetic ketoacidosis (increased ketones in the blood or urine).
  • XYREM® and Narcolepsy Treatment Information Find out more about narcolepsy, excessive daytime sleepiness, cataplexy, and how treatment with XYREM® (sodium oxybate) can help.
  • show more...

Estimated Cost and Revenue value: $0

Daily Ads revenue: $0

Monthly Ads revenue: $0

Yearily Ads revenue: $0

Now loading ...

Other information creation: 10 January 2002 expired: 10 January 2016 information first time archived: 22 May 2002 last time archived: 11 July 2015 how many times: 509

Whois report

Whois Server Version 2.0
Domain names in the .com and .net domains can now be registered
with many different competing registrars. Go to
for detailed information.
   Domain Name: NEULASTA.COM
   Registrar: MARKMONITOR INC.
   Sponsoring Registrar IANA ID: 292
   Whois Server:
   Referral URL:
   Name Server: NS1.AMGENWEBNS.NET
   Name Server: NS2.AMGENWEBNS.NET
   Status: clientDeleteProhibited
   Status: clientTransferProhibited
   Status: clientUpdateProhibited
   Updated Date: 10-dec-2014
   Creation Date: 11-jan-2002
   Expiration Date: 11-jan-2016
>>> Last update of whois database: Mon, 14 Sep 2015 22:40:01 GMT <<<
NOTICE: The expiration date displayed in this record is the date the 
registrar's sponsorship of the domain name registration in the registry is 
currently set to expire. This date does not necessarily reflect the expiration 
date of the domain name registrant's agreement with the sponsoring 
registrar.  Users may consult the sponsoring registrar's Whois database to 
view the registrar's reported date of expiration for this registration.
TERMS OF USE: You are not authorized to access or query our Whois 
database through the use of electronic processes that are high-volume and 
automated except as reasonably necessary to register domain names or 
modify existing registrations; the Data in VeriSign Global Registry 
Services' ("VeriSign") Whois database is provided by VeriSign for 
information purposes only, and to assist persons in obtaining information 
about or related to a domain name registration record. VeriSign does not 
guarantee its accuracy. By submitting a Whois query, you agree to abide 
by the following terms of use: You agree that you may use this Data only 
for lawful purposes and that under no circumstances will you use this Data 
to: (1) allow, enable, or otherwise support the transmission of mass 
unsolicited, commercial advertising or solicitations via e-mail, telephone, 
or facsimile; or (2) enable high volume, automated, electronic processes 
that apply to VeriSign (or its computer systems). The compilation, 
repackaging, dissemination or other use of this Data is expressly 
prohibited without the prior written consent of VeriSign. You agree not to 
use electronic processes that are automated and high-volume to access or 
query the Whois database except as reasonably necessary to register 
domain names or modify existing registrations. VeriSign reserves the right 
to restrict your access to the Whois database in its sole discretion to ensure 
operational stability.  VeriSign may restrict or terminate your access to the 
Whois database for failure to abide by these terms of use. VeriSign 
reserves the right to modify these terms at any time. 
The Registry database contains ONLY .COM, .NET, .EDU domains and
For more information on Whois status codes, please visit